Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise (CARDIBOX) (CARDIBOX)

13. März 2020 aktualisiert von: University Hospital, Clermont-Ferrand

Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise

The high prevalence of childhood obesity is a major public health issue, worldwide. Childhood obesity is associated with a high risk of cardiovascular events in adulthood, but recent studies also point out the development of cardiovascular complications in childhood or adolescence justifying the need for early detection and appropriate therapeutic management to prevent the development of more severe abnormalities. This project proposes to evaluate the myocardial function in a fine and comprehensive way (longitudinal, circumferential and radial linear deformations, and rotation / torsion mechanics) from the deformation imaging (MRI and high-resolution echocardiography), in obese adolescents following a lifestyle intervention combining diet and physical activity.

Studienübersicht

Status

Unbekannt

Detaillierte Beschreibung

The investigators aim to improve knowledge of the association between epicardial adipose tissue, myocardial lipid content, and left ventricular regional myocardial function.

In this protocol, obese adolescents are recruited undergoing a 3-month lifestyle intervention residential program. Adolescents from the intervention group will be enrolled at the obesity center for the whole school year. The obesity center employs a multidisciplinary team to provide the best weight management care to adolescents during their stay. The weight loss program is an integral part of the obesity center program and fundamentally combines physical activity with a normocaloric diet monitored by a dietician. The physical activity program consists of two training sessions (aerobic and resistance training) per week. Moreover, adolescents will be engaged in two additional sessions per week, consisting in recreational activities such as ball and racquet games, trekking, snowshoeing or swimming.

There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only.

Statistical analysis will be performed using Stata software (version 13; Stata-Corp, College Station, Tex., USA). All statistical tests will be two-sided and p inferior to 0.05 will be considered significant. Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of numbers, mean standard deviation or median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results. The main analysis will be performed with the Stata software (version 13, StataCorp, College Station). All statistical tests will be carried out at a risk of error of first species α set at 5%. Most of the analysis of the secondary evaluation criteria will be exploratory in nature and may lack power in terms of numbers. As discussed by Feise in 2002,104 the adjustment of the risk of error of 1st species will not be systematically proposed, but case by case in view of clinical considerations and not only statistical (e.g. Sidak correction for the analysis of correlation coefficients).

Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of standard deviation or mean median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results.

Intergroup comparisons will be systematically conducted without adjustment and by adjusting for factors whose distribution could be unbalanced between groups. Patients will be described and compared between groups at inclusion according to the following variables: compliance with eligibility criteria, epidemiological characteristics, clinical characteristics and characteristics of possible treatments. The baseline comparability of the two groups will be assessed on the main characteristics of the participants and potential factors associated with the primary outcome. A possible difference between the two groups on one of these characteristics will be determined according to clinical considerations and not solely statistical ones.

Studientyp

Interventionell

Einschreibung (Voraussichtlich)

50

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Clermont-Ferrand, Frankreich, 63000
        • CHU de Clermont-Ferrand

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

12 Jahre bis 16 Jahre (Kind)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • age between 12 and 16 years old
  • mature (menarche)
  • suitable for physical activity
  • able to give an informative consent
  • affiliated at French insurance company
  • consent from the legal representatives
  • For obese adolescents: BMI greater than the 97th percentile of national curves.
  • For the control group: to be normal-weighted (no obesity if overweight, <85th percentile of national curves).

Exclusion Criteria:

  • Medical or surgical history judged by the investigator as incompatible with the study
  • Drugs that may interfere with the study results
  • Cardiovascular, hepatic, psychiatric, renal, or endocrinological diseases
  • Smoking
  • Alcohol consumption
  • Intense physical activity in competition

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Verhütung
  • Zuteilung: Nicht randomisiert
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Obese adolescents
BMI greater than the 97th percentile of national curves. Participants will follow a 3-month lifestyle intervention

Adolescents from the intervention group will be enrolled at the obesity center for the whole school year (i.e., 10 months). The physical activity program consists of two training sessions (aerobic and resistance training) per week.

There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only.

Kein Eingriff: Control group
to be normal-weighted (no obesity if overweight, <85th percentile of national curves).

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
cardiac ectopic fat deposits
Zeitfenster: Month 3
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
Month 3
cardiac ectopic fat deposits
Zeitfenster: Day 0
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
Day 0
cardiac ectopic fat deposits
Zeitfenster: Day 0
Quantification of cardiac ectopic fat deposits (volume using MRI)
Day 0
cardiac ectopic fat deposits
Zeitfenster: Month 3
Quantification of cardiac ectopic fat deposits (volume using MRI)
Month 3
cardiac ectopic fat deposits
Zeitfenster: Month 3
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
Month 3
cardiac ectopic fat deposits
Zeitfenster: Day 0
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
Day 0
left myocardial regional function
Zeitfenster: Month 3
left myocardial regional function (echocardiography)
Month 3
left myocardial regional function
Zeitfenster: Month 3
left myocardial regional function (MRI)
Month 3
left myocardial regional function
Zeitfenster: Day 0
left myocardial regional function (echocardiography)
Day 0
left myocardial regional function
Zeitfenster: Day 0
left myocardial regional function (MRI)
Day 0

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
macrovascularisation
Zeitfenster: Day 0
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
Day 0
macrovascularisation
Zeitfenster: Month 3
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
Month 3
microvascularisation
Zeitfenster: Month 3
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
Month 3
microvascularisation
Zeitfenster: Day 0
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
Day 0
microvascularisation
Zeitfenster: Day 0
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
Day 0
microvascularisation
Zeitfenster: Month 3
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
Month 3
microvascularisation
Zeitfenster: Month 3
measure of microvascular perfusion using Iontophoresis procedure
Month 3
microvascularisation
Zeitfenster: Day 0
measure of microvascular perfusion using Iontophoresis procedure
Day 0
microvascularisation
Zeitfenster: Day 0
measure of microvascular perfusion using flowmotion
Day 0
microvascularisation
Zeitfenster: Month 3
measure of microvascular perfusion using flowmotion
Month 3
heart rate variability
Zeitfenster: Month 3
measure of heart rate variability using a holter
Month 3
heart rate variability
Zeitfenster: Day 0
measure of heart rate variability using a holter
Day 0
skin conductance
Zeitfenster: Day 0
measure of skin conductance using Wristband electrodes - Empatica E4
Day 0
skin conductance
Zeitfenster: Month 3
measure of skin conductance using Wristband electrodes - Empatica E4
Month 3
Liver steatosis
Zeitfenster: Month 3
measure of liver steatosis by MRI
Month 3
Liver steatosis
Zeitfenster: Day 0
measure of liver steatosis by MRI
Day 0
Liver steatosis
Zeitfenster: Day 0
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
Day 0
Liver steatosis
Zeitfenster: Month 3
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
Month 3
Liver steatosis
Zeitfenster: month 3
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
month 3
Liver steatosis
Zeitfenster: Day 0
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
Day 0
Liver fibrosis
Zeitfenster: Day 0
measure of liver fibrosis by fibroscanner (liver stiffness)
Day 0
Liver fibrosis
Zeitfenster: Month 3
measure of liver fibrosis by fibroscanner (liver stiffness)
Month 3
Liver fibrosis
Zeitfenster: Month 3
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
Month 3
Liver fibrosis
Zeitfenster: Day 0
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
Day 0
blood pressure
Zeitfenster: Day0
measure of blood pressure using sphygmomanometer
Day0
blood pressure
Zeitfenster: month 3
measure of blood pressure using sphygmomanometer
month 3
Fitness
Zeitfenster: Month 3
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
Month 3
Fitness
Zeitfenster: Day 0
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
Day 0
muscle mass
Zeitfenster: Month 3
measure of muscle mass using impedancemeter
Month 3
fat mass
Zeitfenster: Month 3
measure of muscle mass using impedancemeter
Month 3
bone structure
Zeitfenster: Month 3
measure of muscle mass using impedancemeter
Month 3
muscle mass
Zeitfenster: Day 0
measure of muscle mass using impedancemeter
Day 0
fat mass
Zeitfenster: Day 0
measure of muscle mass using impedancemeter
Day 0
bone structure
Zeitfenster: Day 0
measure of muscle mass using impedancemeter
Day 0
muscle mass
Zeitfenster: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
fat mass
Zeitfenster: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
bone structure
Zeitfenster: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
muscle mass
Zeitfenster: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
fat mass
Zeitfenster: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
bone structure
Zeitfenster: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
muscle mass
Zeitfenster: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
fat mass
Zeitfenster: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
bone structure
Zeitfenster: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
muscle mass
Zeitfenster: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
fat mass
Zeitfenster: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
bone structure
Zeitfenster: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
muscle mass
Zeitfenster: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
fat mass
Zeitfenster: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
bone structure
Zeitfenster: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
muscle mass
Zeitfenster: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
fat mass
Zeitfenster: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
bone structure
Zeitfenster: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
depression
Zeitfenster: Day 0
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
Day 0
depression
Zeitfenster: Month 3
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
Month 3
anxiety
Zeitfenster: Day 0
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always". It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
Day 0
anxiety
Zeitfenster: Month 3
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always". It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
Month 3
General health
Zeitfenster: Day 0
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
Day 0
General health
Zeitfenster: Month 3
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
Month 3
Stress
Zeitfenster: day 0
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
day 0
Stress
Zeitfenster: Month 3
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Month 3
Fatigue
Zeitfenster: Day 0
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Day 0
Fatigue
Zeitfenster: Month 3
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Month 3
Sleep
Zeitfenster: day 0
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
day 0
Sleep
Zeitfenster: Month 3
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
Month 3
Burnout
Zeitfenster: day 0
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
day 0
Burnout
Zeitfenster: Month 3
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
Month 3
Mindfulness
Zeitfenster: Day 0
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
Day 0
Mindfulness
Zeitfenster: Month 3
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
Month 3
Coping
Zeitfenster: Day 0
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
Day 0
Coping
Zeitfenster: Month 3
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
Month 3
Emotions
Zeitfenster: Day 0
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
Day 0
Emotions
Zeitfenster: Month 3
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
Month 3
Perception of work
Zeitfenster: Day 0
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree). It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
Day 0
Perception of work
Zeitfenster: Month 3
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree). It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
Month 3
Self-efficacy
Zeitfenster: Day 0
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
Day 0
Self-efficacy
Zeitfenster: Month 3
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
Month 3
Alexithymia
Zeitfenster: Day 0
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
Day 0
Alexithymia
Zeitfenster: Month 3
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
Month 3
Illness perception
Zeitfenster: Day 0
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
Day 0
Illness perception
Zeitfenster: Month 3
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
Month 3
Metacognition
Zeitfenster: Day 0
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
Day 0
Metacognition
Zeitfenster: Month 3
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
Month 3
Time perception
Zeitfenster: Day 0
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale. It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
Day 0
Time perception
Zeitfenster: Month 3
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale. It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
Month 3
Physical activity
Zeitfenster: Day 0
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
Day 0
Physical activity
Zeitfenster: Month 3
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
Month 3
Life style
Zeitfenster: Day 0
life style is assessed with a questionnaire on coffee consumption, food intake, etc
Day 0
Life style
Zeitfenster: Month 3
life style is assessed with a questionnaire on coffee consumption, food intake, etc
Month 3
cholesterol
Zeitfenster: Day 0
measure by blood analyses to evaluate alloplastic load
Day 0
triglycerides
Zeitfenster: Day 0
measure by blood analyses to evaluate alloplastic load
Day 0
cholesterol
Zeitfenster: Month 3
measure by blood analyses to evaluate alloplastic load
Month 3
triglycerides
Zeitfenster: Month 3
measure by blood analyses to evaluate alloplastic load
Month 3
Cortisol
Zeitfenster: Day 0
hormone measure by blood analyses to evaluate alloplastic load
Day 0
Cortisol
Zeitfenster: Month 3
hormone measure by blood analyses to evaluate alloplastic load
Month 3
DHEAS
Zeitfenster: day 0
hormone measure by blood analyses to evaluate alloplastic load
day 0
DHEAS
Zeitfenster: Month 3
hormone measure by blood analyses to evaluate alloplastic load
Month 3
BDNF
Zeitfenster: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
BDNF
Zeitfenster: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
CRP
Zeitfenster: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
pro-inflammatory cytokines
Zeitfenster: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
TNF alpha
Zeitfenster: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
CRP
Zeitfenster: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
pro-inflammatory cytokines
Zeitfenster: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
TNF alpha
Zeitfenster: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
NPY
Zeitfenster: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
NPY
Zeitfenster: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
Leptin
Zeitfenster: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Leptin
Zeitfenster: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
Ghrelin
Zeitfenster: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Ghrelin
Zeitfenster: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
NPY
Zeitfenster: day 0
measure by blood analyses to evaluate appetite regulation
day 0
NPY
Zeitfenster: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
adiponectine
Zeitfenster: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
adiponectine
Zeitfenster: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
CCK
Zeitfenster: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Month 3
Zeitfenster: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Insulin
Zeitfenster: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
Insulin
Zeitfenster: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
HbA1c
Zeitfenster: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
HbA1c
Zeitfenster: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
glucose
Zeitfenster: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
glucose
Zeitfenster: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
Albumin
Zeitfenster: Day 0
measure by blood analyses to evaluate protid metabolism
Day 0
Albumin
Zeitfenster: Month 3
measure by blood analyses to evaluate protid metabolism
Month 3
transthyretin
Zeitfenster: Day 0
measure by blood analyses to evaluate protid metabolism
Day 0
transthyretin
Zeitfenster: Month 3
measure by blood analyses to evaluate protid metabolism
Month 3
Homeostasis
Zeitfenster: Day 0
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
Day 0
Homeostasis
Zeitfenster: Month 3
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
Month 3
Osteoresorption
Zeitfenster: Day 0
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
Day 0
Osteoresorption
Zeitfenster: Month 3
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
Month 3
Osteoformation
Zeitfenster: Day 0
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
Day 0
Osteoformation
Zeitfenster: Month 3
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
Month 3
VEGF
Zeitfenster: Day 0
measure by blood analyses to evaluate cardiovascular function
Day 0
VEGF
Zeitfenster: Month 3
measure by blood analyses to evaluate cardiovascular function
Month 3
PAI1
Zeitfenster: Day 0
measure by blood analyses to evaluate cardiovascular function
Day 0
PAI1
Zeitfenster: Month 3
measure by blood analyses to evaluate cardiovascular function
Month 3
weight
Zeitfenster: Day 0
measure of weight in kilograms
Day 0
weight
Zeitfenster: Month 3
measure of weight in kilograms
Month 3
waist circumference
Zeitfenster: Day 0
measure of waist circumference in centimetres
Day 0
waist circumference
Zeitfenster: Month 3
measure of waist circumference in centimetres
Month 3

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Voraussichtlich)

1. September 2020

Primärer Abschluss (Voraussichtlich)

1. Juni 2021

Studienabschluss (Voraussichtlich)

1. Juni 2021

Studienanmeldedaten

Zuerst eingereicht

10. Februar 2020

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

13. März 2020

Zuerst gepostet (Tatsächlich)

17. März 2020

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

17. März 2020

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

13. März 2020

Zuletzt verifiziert

1. Februar 2020

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • RBHP 2019 DUTHEIL
  • 2019-A01804-53 (Andere Kennung: ANSM)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

Unentschieden

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur 3-month lifestyle intervention

Abonnieren